These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 489770)

  • 21. Pharmacologic considerations in determining efficacy of once-daily sotalol administration to hypertensive patients.
    Pasquel R
    J Clin Pharmacol; 1979; 19(8-9 Pt 2):523-32. PubMed ID: 489771
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Vasodepressor reaction induced by inferior vena cava occlusion and isoproterenol in the rat. Role of beta 1- and beta 2-adrenergic receptors.
    Waxman MB; Asta JA; Cameron DA
    Circulation; 1994 May; 89(5):2401-11. PubMed ID: 7910121
    [TBL] [Abstract][Full Text] [Related]  

  • 23. d-sotalol reduces heart rate in vivo through a beta-adrenergic receptor-independent mechanism.
    Yasuda SU; Barbey JT; Funck-Brentano C; Wellstein A; Woosley RL
    Clin Pharmacol Ther; 1993 Apr; 53(4):436-42. PubMed ID: 8386603
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Propranolol and sotalol as antagonists of isoproterenol-enhanced physiologic tremor.
    Pickles H; Perucca E; Fish A; Richens A
    Clin Pharmacol Ther; 1981 Sep; 30(3):303-10. PubMed ID: 6115732
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of oral charcoal and urine pH on sotalol pharmacokinetics.
    Kärkkäinen S; Neuvonen PJ
    Int J Clin Pharmacol Ther Toxicol; 1984 Aug; 22(8):441-6. PubMed ID: 6092287
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of oral sotalol in suppression of premature ventricular complexes and analysis of its beta-adrenergic blocking activity.
    Giorgi C; Nadeau R; Agha A; Primeau R; de Champlain J
    Can J Cardiol; 1990 Jun; 6(5):191-7. PubMed ID: 1696514
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of adrenergic-blocking or -stimulating agents on plasma growth hormone, immunoreactive insulin, and blood free fatty acid levels in man.
    Imura H; Kato Y; Ikeda M; Morimoto M; Yawata M
    J Clin Invest; 1971 May; 50(5):1069-79. PubMed ID: 4928263
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The pharmacokinetics and pharmacodynamics of sulfinalol hydrochloride in dogs after intravenous administration.
    Park GB; Koss RF; DeFelice AF; O'Neil SK; Edelson J
    Arch Int Pharmacodyn Ther; 1982 Sep; 259(1):4-13. PubMed ID: 6129834
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Beta-adrenergic blocking property of dl-sotalol maintains class III efficacy in guinea pig ventricular muscle after isoproterenol.
    Groh WJ; Gibson KJ; McAnulty JH; Maylie JG
    Circulation; 1995 Jan; 91(2):262-4. PubMed ID: 7805226
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of selective (beta-1 and beta-2) and nonselective beta adrenoceptor antagonists on the cardiovascular and metabolic responses to isoproterenol: comparison with ICI 141,292.
    Smith HJ; Halliday SE; Earl DC; Stribling D
    J Pharmacol Exp Ther; 1983 Jul; 226(1):211-6. PubMed ID: 6134820
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A mechanism of D-(+)-sotalol effects on heart rate not related to beta-adrenoceptor antagonism.
    Funck-Brentano C; Silberstein DJ; Roden DM; Wood AJ; Woosley RL
    Br J Clin Pharmacol; 1990 Aug; 30(2):195-202. PubMed ID: 2169833
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effect of end-stage renal failure and haemodialysis on the elimination kinetics of sotalol.
    Tjandramaga TB; Verbeeck R; Thomas J; Verbesselt R; Verberckmoes R; Schepper PJ
    Br J Clin Pharmacol; 1976 Apr; 3(2):259-65. PubMed ID: 973960
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sotalol: another beta adrenergic blocking agent?
    Ahlquist RP
    J Clin Pharmacol; 1979; 19(8-9 Pt 2):495-6. PubMed ID: 489768
    [No Abstract]   [Full Text] [Related]  

  • 34. Differentiation of metabolic adrenoceptors.
    Loakpradit T; Lockwood R
    Br J Pharmacol; 1977 Jan; 59(1):135-40. PubMed ID: 13899
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sotalol kinetics in renal insufficiency.
    Blair AD; Burgess ED; Maxwell BM; Cutler RE
    Clin Pharmacol Ther; 1981 Apr; 29(4):457-63. PubMed ID: 7471612
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Renin-angiotensin-aldosterone system in the treatment of essential hypertension with a beta-adrenergic blocker: sotalol].
    Psadas C; Sánchez G; Zaldívar HM; Rangel J; Cuéllar A; Serrano PA
    Arch Inst Cardiol Mex; 1977; 47(2):160-70. PubMed ID: 901052
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Treatment of hypertension with Sotalol (author's transl)].
    Fillastre JP; Godin M; Joire JE; Gauthier A
    Sem Hop; 1979 Nov 18-25; 55(39-40):1825-31. PubMed ID: 232780
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of sotalol and vagal stimulation on ischemic myocardial blood flow distribution in the canine heart.
    Buck JD; Warltier DC; Hardman HF; Gross GJ
    J Pharmacol Exp Ther; 1981 Feb; 216(2):347-51. PubMed ID: 7463353
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of 1-(4-nitrophenyl)-2-isopropylaminoethanol (INPEA) and propranolol and their dextro-isomers on hemodynamic and metabolic responses to isoproterenol in dogs.
    Nishimura T; Kita S; Abiko Y
    J Pharmacol Exp Ther; 1983 Aug; 226(2):595-602. PubMed ID: 6688273
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Comparative beta-adrenoceptor blocking effects and pharmacokinetics of sotalol and propranolol in healthy volunteers].
    Richer C; Maury M; Poirier JM; Duhaze P; Giudicelli JF
    Therapie; 1982; 37(3):259-67. PubMed ID: 6753226
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.